BPCR vs. ABDN, ATST, 3IN, PHLL, JGGI, BPT, RCP, MNKS, BUR, and HVPE
Should you be buying BioPharma Credit stock or one of its competitors? The main competitors of BioPharma Credit include abrdn (ABDN), Alliance Trust (ATST), 3i Infrastructure (3IN), Petershill Partners (PHLL), JPMorgan Global Growth & Income (JGGI), Bridgepoint Group (BPT), RIT Capital Partners (RCP), Monks (MNKS), Burford Capital (BUR), and HarbourVest Global Private Equity (HVPE). These companies are all part of the "asset management" industry.
BioPharma Credit vs. Its Competitors
abrdn (LON:ABDN) and BioPharma Credit (LON:BPCR) are both financial services companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.
abrdn has a beta of 1.25, suggesting that its share price is 25% more volatile than the S&P 500. Comparatively, BioPharma Credit has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500.
38.2% of abrdn shares are held by institutional investors. Comparatively, 41.5% of BioPharma Credit shares are held by institutional investors. 2.4% of abrdn shares are held by company insiders. Comparatively, 6.2% of BioPharma Credit shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
BioPharma Credit has a net margin of 80.20% compared to abrdn's net margin of 21.19%. BioPharma Credit's return on equity of 8.51% beat abrdn's return on equity.
abrdn pays an annual dividend of GBX 15 per share and has a dividend yield of 7.7%. BioPharma Credit pays an annual dividend of GBX 7 per share and has a dividend yield of 788.3%. abrdn pays out 85.3% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. BioPharma Credit pays out 7,957.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future.
abrdn currently has a consensus target price of GBX 195.60, indicating a potential upside of 0.88%. Given abrdn's stronger consensus rating and higher probable upside, equities analysts clearly believe abrdn is more favorable than BioPharma Credit.
BioPharma Credit has higher revenue and earnings than abrdn. BioPharma Credit is trading at a lower price-to-earnings ratio than abrdn, indicating that it is currently the more affordable of the two stocks.
In the previous week, abrdn had 1 more articles in the media than BioPharma Credit. MarketBeat recorded 1 mentions for abrdn and 0 mentions for BioPharma Credit. abrdn's average media sentiment score of 0.20 beat BioPharma Credit's score of 0.00 indicating that abrdn is being referred to more favorably in the media.
Summary
abrdn beats BioPharma Credit on 10 of the 18 factors compared between the two stocks.
Get BioPharma Credit News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPCR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding BPCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BioPharma Credit Competitors List
Related Companies and Tools
This page (LON:BPCR) was last updated on 8/16/2025 by MarketBeat.com Staff
MarketBeat All Access